ABBVAbbVie Inc.

NYSE abbvie.com


$ 170.76 $ -1.99 (-1.15 %)    

Tuesday, 25-Jun-2024 15:59:56 EDT
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 170.75
$ 172.42
$ 0.00 x 0
$ 0.00 x 0
$ 170.62 - $ 173.37
$ 125.85 - $ 181.20
4,844,490
na
302.74B
$ 0.64
$ 50.52
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-03-2024 03-31-2024 10-Q
2 02-20-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-05-2023 03-31-2023 10-Q
6 02-17-2023 12-31-2022 10-K
7 11-04-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-06-2022 03-31-2022 10-Q
10 02-18-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 08-02-2021 06-30-2021 10-Q
13 05-07-2021 03-31-2021 10-Q
14 02-19-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-04-2020 06-30-2020 10-Q
17 05-08-2020 03-31-2020 10-Q
18 02-21-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-05-2019 06-30-2019 10-Q
21 05-03-2019 03-31-2019 10-Q
22 02-27-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-04-2018 03-31-2018 10-Q
26 02-16-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-07-2017 06-30-2017 10-Q
29 05-05-2017 03-31-2017 10-Q
30 02-17-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-Q
33 05-06-2016 03-31-2016 10-Q
34 02-19-2016 12-31-2015 10-K
35 11-06-2015 09-30-2015 10-Q
36 08-07-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 02-20-2015 12-31-2014 10-K
39 11-07-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 abbvies-parkinsons-disease-therapy-hits-fda-roadblock

AbbVie received an FDA Complete Response Letter for ABBV-951 (foscarbidopa/foslevodopa) due to third-party manufacturing issues...

 abbvie-receives-a-complete-response-letter-from-us-fda--for-the-nda-for-abbv-951-for-the-treatment-of-motor-fluctuations-in-adults-with-advanced-parkinsons-disease

U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for ABBV-951 based on observations from an inspec...

 cantor-fitzgerald-reiterates-overweight-on-abbvie-maintains-200-price-target

Cantor Fitzgerald analyst Louise Chen reiterates AbbVie (NYSE:ABBV) with a Overweight and maintains $200 price target.

 piper-sandler-maintains-overweight-on-abbvie-raises-price-target-to-190

Piper Sandler analyst Christopher Raymond maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $1...

 nvidia-abbvie-vertex-pharmaceuticals-and-an-oil-giant-cnbcs-final-trades

On CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals, Kevin Simpson named C...

 abbvie-recommends-shareholders-reject-tutanotas-mini-tender-offer-to-purchase-up-to-250k-shares-of-common-stock-at-165-per-share-in-cash

AbbVie (NYSE:ABBV) has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited "mini-tender" offer, dat...

 abbvie-exec-says-co-will-continue-to-pursue-deals-in-immunology

- Reuters

 abbvie-exec-says-co-expects-a-step-down-in-humira-revenue-in-2025

- Reuters

 goldman-sachs-optimistic-about-regenxbios-gene-therapy-pipeline-sees-over-160-upside

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.